Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Zolgensma (onasemnogene abeparvovec)
Marketing
Novartis, Sarepta tipped to drive genomic therapy sales boom
GlobalData tipped the market to balloon to almost $90 billion by 2030, driven by gene therapies such as Sarepta’s Elevidys and Novartis’ Zolgensma.
Nick Paul Taylor
May 15, 2025 12:18pm
Novartis peels back Zolgensma IT data in older SMA patients
Mar 19, 2025 9:00am
Roche picks up FDA nod for easier Evrysdi dosing format in SMA
Feb 12, 2025 2:30pm
Novartis readies intrathecal Zolgensma for older SMA patients
Jan 2, 2025 12:30pm
BMS takes over Novartis' gene therapy plant in Illinois
Apr 26, 2023 10:25am
Performance slump takes toll on Novartis' CEO's 2022 payout
Mar 8, 2023 9:33am
